AI Article Synopsis
- Studies indicate that 30-50% of non-small cell lung cancer (NSCLC) patients develop brain metastasis (BM), which negatively impacts survival and quality of life, highlighting the need for early detection and treatment.
- A study involving 117 NSCLC patients with BM and 237 without BM evaluated various histopathological factors via a pathologist's analysis of tissue samples.
- Results show that in pulmonary adenocarcinoma, factors like vascular invasion, N stage, micropapillary pattern, and extensive necrosis are significantly linked to BM, with extensive necrosis indicating a higher risk for developing BM.
Article Abstract
Background: Studies have shown that 30-50% of non-small cell lung cancer (NSCLC) patients develop brain metastasis (BM). Since BM shortens overall survival and decreases the quality of life, early detection and treatment of BM are vital. While data are available for clinical risk factors of NSCLC with BM, histopathological factors are not well understood. Therefore, we evaluated the histopathological related factors which will help early detection and selection of effective treatment options.
Materials And Methods: A total of 117 surgical lung specimens diagnosed as NSCLC with BM were included as a study group. We included 237 cases without BM as a control group. One pathologist reviewed H&E slides and analyzed the histopathologic factors of all cases.
Results: In pulmonary adenocarcinoma, vascular invasion, N stage, micropapillary pattern and necrosis were significantly associated with BM in multivariate analysis (vascular invasion, p = 0.009; micropapillary pattern, p = 0.024; others, p < 0.001). Tumor with extensive necrosis had higher hazard ratio and shorter time to BM (p < 0.001).
Conclusion: Our findings suggest that necrosis is a new predictive factor of BM in pulmonary adenocarcinoma. Short term follow-up is needed especially when extensive necrosis is present.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.prp.2019.01.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mucin5AC promotes breast cancer brain metastasis through cMET/CD44v6.
Clin Cancer Res
January 2025
University of Nebraska Medical Center, OMAHA, NE, United States.
Purpose: Breast cancer (BC) brain metastasis (BrM) remains a significant clinical problem. Mucins have been implicated in metastasis; however, if they are also involved in BCBrM remains unknown. We queried BrM patient databases and found Mucin 5AC (MUC5AC) to be upregulated and therefore sought to define the role of MUC5AC in BCBrM.
View Article and Find Full Text PDFSynthesis and Biological Evaluation of Peripheral HTR2A Antagonists for Colorectal Cancer.
J Med Chem
January 2025
Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea.
Colorectal cancer is a prevalent and prominent contributor to global cancer-related fatalities with challenges in drug resistance and metastasis. Recent research highlights the potential relationship between serotonin and cancer. 5-Hydroxytryptamine receptor 2A (HTR2A) mRNA expression in colorectal cancer cells was found to be notably elevated compared to that in normal colon cells.
View Article and Find Full Text PDFRepeat GammaTile Brachytherapy in the Long-Term Management of Recurrent High-Grade Glioma: A Case Report.
Cureus
December 2024
Neurological Surgery, Upstate University Hospital, Syracuse, USA.
Over the past two decades, despite the emergence of various novel therapies for glioblastoma, patient survival outcomes remain poor, particularly in the recurrent stage of the disease. Cesium-131 (Cs-131) brachytherapy presents a promising treatment option for patients with newly diagnosed and recurrent brain neoplasms, enabling the initiation of radiation therapy at the time of tumor resection. This approach eliminates the typical delay in therapy following surgery and the need for multiple return visits for fractionated external beam radiotherapy.
View Article and Find Full Text PDFSuccessful osimertinib treatment for Meckel's cave metastasis: a case report.
Int Cancer Conf J
January 2025
Department of Respiratory Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa Japan.
Osimertinib has emerged as the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations, offering improved tolerability and demonstrating superior efficacy against brain metastases in comparison with other tyrosine kinase inhibitors. The Meckel's cave is a dural recess in the posteromedial part of the middle cranial fossa that acts as a conduit for the trigeminal nerve between the anterior pontine cisterna and the cavernous sinus, and houses the Gasserian ganglion and proximal radicle of the trigeminal nerve. Trigeminal neuropathy, characterized by numbness and dysesthesia of the skin and mucous membranes of the face, poses diagnostic challenges and often requires differentiation from conditions, such as compression neuropathy, inflammation, and drug-induced reactions.
View Article and Find Full Text PDFChanging Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis.
JTO Clin Res Rep
January 2025
Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Introduction: Osimertinib is now a standard first-line (1L) therapy for EGFR-mutated (EGFRm) advanced NSCLC. We aimed to characterize patterns of therapy and longitudinal risk of brain and liver metastasis in a cohort of EGFRm NSCLC.
Methods: Patients with metastatic EGFRm NSCLC who received 1L systemic therapy at sites within the Academic Thoracic Medical Investigator's Consortium were included; demographic and clinical data including treatment patterns were described.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!